Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Halozyme Therapeutics Inc.

www.halozyme.com

Latest From Halozyme Therapeutics Inc.

Deal Watch: Amgen Outsources Celiac Drug To Provention; Lilly, NextCure Will Co-Discover IO Drugs

Through its Provention collaboration, Amgen partnered with the team that worked on AMG 714 at Celimmune, which the big biotech bought in 2017. Lilly will partner with NextCure to use the latter's FIND-IO platform for immuno-oncology drug discovery.

Deals Business Strategies

Taking Action On Diversity, BIO Challenges CEOs To Pursue Business Benefits

Scrip spoke with Halozyme CEO Helen Torley, chair of BIO's Workforce Development, Diversity and Inclusion committee, about efforts to communicate the benefits of diverse leadership to CEOs and build a database of diverse board candidates.

Human Capital Leadership

Appointments: News From GSK, DBV Technologies, Complexa, Synlogic And Motif Bio

This week’s announcements include the retirement of GlaxoSmithKline’s CFO, new CEOs at Complexa, Synlogic and Horizon Discovery, and other new hires at TP Therapeutics and Motif Bio, and a new board member at DBV Technologies.

Appointments BioPharmaceutical

This Isn't The Big One: Darzalex Wins US Approval In First-Line Multiple Myeloma

Janssen Biotech has won FDA approval for Genmab-licensed Darzalex in newly diagnosed multiple myeloma. However, the drug was approved in a combination that is not commonly used in the US. A further label expansion will provide a bigger boost to the anti-CD38 antibody's commercial prospects.

Approvals United States
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Hyalozyme Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Halozyme Therapeutics Inc.
  • Senior Management
  • Helen Torley, Pres. & CEO
    Laurie Stelzer, SVP, CFO
    Michael J LaBarre, PhD, VP, CSO
    Kenneth A Schultz, MD, VP, Innovation, Strategy & Bus. Dev.
    Benjamin Hickey, Chief Commercial Officer
  • Contact Info
  • Halozyme Therapeutics Inc.
    Phone: (858) 794-8889
    11388 Sorrento Valley Rd.
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register